All Dr Kathleen Mulvaney (Assistant Professor the Fralin Biomedical Research Institute’s Cancer Research Center) articles
-
NewsNew drug combo targets PRMT5 to fight deadly cancers
Scientists at Virginia Tech’s Fralin Biomedical Research Institute have identified a promising drug target – PRMT5 – that could make treatment-resistant lung, brain and pancreatic cancers more vulnerable to therapy.